Fundamentals Data provided by Morningstar.Data provided by Morningstar.
52 Week Range
Avg. Volume (1 month)
as at 24 Feb 3:44pm
Should you invest $1,000 in right now?
Before you consider , you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.
The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of August 16th 2021
40% recovery: 4DMedical share price (ASX:4DX) turns sharply and delivers the goods
Why is the 4DMedical (ASX:4DX) share price rocketing 30% today?
4DMedical (ASX:4DX) share price launches 19% on first commercial scans
4DMedical (ASX:4DX) share price gains amid boss’ confidence for FY22
Share Market News
ASX 200 falls, Metcash down, 4DMedical drops
4DMedical (ASX:4DX) share price is lifting on its COVID-related technology
4DMedical (ASX:4DX) share price lifts on 71% income increase in FY21
4DMedical (ASX:4DX) share price soars on contract with $305b pharma giant
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
|Date||Announcement||Price Sensitive?||Time||No. of Pages||File Size|
4DMedical Ltd is a company whose principal activities is medical research technology and the development of a non-invasive respiratory imaging solution using four-dimensional imaging. The four-dimensional lung imaging technology utilises mathematics models and algorithms to convert X-ray scans into quantitative data which helps the physicians to manage patients with respiratory diseases and diseases of the lung.
|13 May 2022||$0.76||$-0.02||-2.58%||204,327||$0.77||$0.77||$0.72|
|12 May 2022||$0.78||$0.11||16.42%||509,602||$0.68||$0.79||$0.65|
|11 May 2022||$0.67||$0.07||11.67%||265,303||$0.60||$0.69||$0.59|
|10 May 2022||$0.60||$0.03||5.22%||265,107||$0.58||$0.60||$0.57|
|09 May 2022||$0.58||$-0.05||-8.06%||248,441||$0.63||$0.63||$0.57|
|06 May 2022||$0.62||$-0.04||-6.11%||264,175||$0.62||$0.63||$0.61|
|05 May 2022||$0.66||$0.00||0.00%||249,586||$0.66||$0.66||$0.62|
|04 May 2022||$0.66||$-0.02||-2.96%||392,924||$0.67||$0.67||$0.62|
|03 May 2022||$0.68||$-0.05||-6.85%||347,799||$0.71||$0.72||$0.68|
|02 May 2022||$0.73||$0.00||0.00%||192,160||$0.71||$0.73||$0.68|
|29 Apr 2022||$0.73||$0.03||4.26%||245,842||$0.71||$0.73||$0.70|
|28 Apr 2022||$0.71||$-0.03||-4.08%||557,302||$0.71||$0.73||$0.70|
|27 Apr 2022||$0.74||$-0.02||-2.65%||352,060||$0.73||$0.76||$0.70|
|26 Apr 2022||$0.76||$-0.02||-2.60%||222,326||$0.76||$0.76||$0.72|
|22 Apr 2022||$0.77||$0.01||1.32%||210,491||$0.75||$0.78||$0.75|
|21 Apr 2022||$0.76||$0.02||2.68%||146,940||$0.75||$0.78||$0.75|
|20 Apr 2022||$0.75||$-0.02||-2.63%||150,999||$0.76||$0.77||$0.73|
|22 Mar 2022||Andreas Fouras||Buy||11||$10,000||
On-market trade. As per announcement on 25-03-2022
|Mr Bruce Rathie||Non-Executive ChairmanNon-Executive Director||Dec 2019||
Mr Rathie is a professional Non Executive Director of 20 years, having completed successful prior careers in law and finance. He is strong in governance. His legal career included being partner of a prominent private law firm, then Senior Corporate Counsel to Robert Holmes a Court's Bell Resources Limited in the 1980s. After completing his MBA in Switzerland, he went into investment banking in 1986 which took him to New York for three years returning to Sydney in 1990. He spent the 1990s as an investment banker in Sydney, the last five as Director Investment Banking and Head of the Industrial Franchise Group at Salomon Brothers and then Salomon Smith Barney where he lead the firm's joint lead manager roles in the privatisations or IPOs of Qantas, Commonwealth Bank and Telstra amongst other major transactions of the day. He has been a professional director since 2000 in roles with ASX listed and unlisted companies predominantly in the financial services, biotechnology and technology sectors. He is currently a Non Executive Director of ASX 200 PolyNovo Limited, Capricorn Society Limited, ASX listed Cettire Limited and Australian Meat Processors Corporation Limited. He is also Chairman of Capricorn Mutual Limited and 4DMedical. Previously, he has been a Non Executive Director of ASX listed companies Netlinkz Limited, Compumedics Limited, Anteo Diagnostics Limited (Chairman), USCOM Limited, Mungana Goldmines Limited and Datadot Technology Limited (Chairman). He also served as an inaugural CSIRO nominated Non Executive Director of Polynovo Biomaterials Pty Ltd when the Polynovo technology was first spun out of the CSIRO in 2004, as with several other CSIRO technology commercialisations and served as chairman of a number of these vehicles
|Mr John Andrew Livingston||Non-Executive Director||Mar 2018||
Mr Livingston was previously one of the founding partners of Lake Imaging, subsequently becoming part of Integral Diagnostics Ltd., where Mr Livingston was Chief Executive Officer and Managing Director. Mr Livingston was awarded the AGFA International Award for Development of Digital Imaging Solutions in 2005. He has lectured in Australia and abroad on the digital radiology environment, as well as business strategies and systems within the commercial sector. Mr Livingston has considerable commercial experience, having worked with the team at Lake Imaging and later Integral Diagnostics through acquisitions and the establishment of Greenfield facilities across Australia. During his career at Integral Diagnostics, Mr Livingston lead the group through private equity investment with Advent Partners in 2014 and in 2015 Mr Livingston worked with Advent to list Integral Diagnostics on the ASX. Mr Livingston is a former director of VicWest Community Telco and United Way; a current director at QScan, Comrad Medical Systems and Ballarat Clarendon College (Chairman). Mr Livingston is Chair of the Remuneration and Nomination Committee
|Ms Evonne Maree Collier||Non-Executive Director||Dec 2021||
Ms Collier is a professional director and an experienced leader in business scale-up, transformation and digital disruption, and has multinational experience across SaaS, sales and marketing in industries spanning MedTech, FinTech, pharmaceutical/health, eCommerce/Digital and FMCG. Ms Collier has served as non-executive director on various boards since 2011 and currently serves as non-executive director of global SaaS analytics company, Sage Automation, digi-healthtech, Curae Health, SaaS FinTech, Sniip, and Motorama Group Holdings. Ms Collier was previously non-executive director of ASX listed entities 1300Smiles (ASX:ONT) and Vault Intelligence (ASX:VLT).
|Dr Robert Alan Figlin||Non-Executive Director||Dec 2016||
Dr Figlin is the Steven Spielberg Family Chair in Hematology Oncology, Professor of Medicine and Biomedical Sciences, Deputy Director for Cedars Sinai Cancer, and Deputy Director of the Samuel Oschin Comprehensive Cancer Institute. Dr Figlin received his medical degree from the Medical College of Pennsylvania. He completed his residency and chief residency in internal medicine at Cedars Sinai Medical Center and a fellowship in hematology/oncology at the David Geffen School of Medicine at UCLA. He is an Emeritus Professor of Medicine and Urology at the David Geffen School of Medicine at UCLA. Prior to joining Cedars Sinai, Dr Figlin was the Arthur and Rosalie Kaplan Endowed Chair of the Department of Medical Oncology and Therapeutics Research, and the Associate Director for Clinical Research at the City of Hope Comprehensive Cancer Center. Prior to that, Dr Figlin served as the Henry Alvin and Carrie L. Meinhardt Endowed Chair in Urologic Oncology and Professor of Medicine and Urology in the Divisions of Hematology/Oncology and Urologic Oncology at the David Geffen School of Medicine at UCLA. Dr Figlin joined the UCLA faculty as Assistant Professor of Medicine in the Division of Hematology/Oncology and was Co Director of the Jonsson Comprehensive Cancer Center's Oncology Program. He held the post of Medical Director of the Thoracic and Genitourinary Oncology Program in the Departments of Medicine, Surgery and Urology, and served as Program Director of Solid Tumor Developmental Therapeutics within the Cancer Center. Dr Figlin serves as Editor for Kidney Cancer Journal, and his studies have appeared in Clinical Cancer Research, Journal of Clinical Oncology, New England Journal of Medicine, The Lancet, JNCI, Lancet Oncology, and Journal of Urology, among others. He has authored over 400 peer reviewed articles, more than 70 book chapters, and has published as editor multiple books in kidney cancer. A nationally recognised leader in genitourinary and thoracic oncology in the United States, Dr Figlin's research focuses on renal cell carcinoma and thoracic malignancies. He established and directs the Kidney Cancer Program at Cedars Sinai Medical Center, which aims to understand the biology of kidney cancer and translate that knowledge into novel treatment approaches. His leadership is in developing novel anticancer drugs that avoid the toxicity associated with standard treatments furthers Cedars Sinai's tradition of compassionate patient care
|Dr Andreas Fouras||Chief Executive OfficerManaging Director||Dec 2012||
Mr Fouras started his career in academic research studying experimental fluid dynamics. His early research in wind tunnel quantification placed him as a young leader in the area of imaging (within fluid dynamics) developing a number of new approaches to the imaging of gas and liquid flow. Completing a Masters and PhD, and then rapidly rising to the position of Professor of Mechanical and Aerospace Engineering and Director of the Laboratory for Dynamic Imaging, Mr Fouras was recognised by various accolades from a wide range of premier research bodies including the National Health and Medical Research Council and the American Asthma Foundation. Mr Fouras was able to apply novel concept to clinical use through the development of XV Technology, uniquely measuring airflow within the breathing lungs, at every stage of the breath, with both high spatial and temporal resolution at very low dose. Mr Fouras' research has been documented in over 100 peer reviewed publications and over 40 patents and patent applications. Mr Fouras founded 4DMedical in December 2012 from a desire for his work to reach and positively influence as many people globally as possible. A recognised leader, as evidenced by an Australian Davos Connection Australian Leadership Award (2013), Mr Fouras is now dedicated to applying his business acumen, drive and innovation to the commercialisation of 4DMedical's technologies
|Ms Lilian (Lil) Bianchi||Non-Executive Director||Dec 2019||
Ms Bianchi brings to 4DMedical an invaluable history of experience in technology products and business transformations, helping lead boards to build an agile and robust strategy through expansive growth. She has participated in business transformations for U.S. listed technology companies and risk collaborations across financial risk modelling, climate science and primary industry productivity models. She is an experienced contributor to business transformations for U.S.listed technology companies with technology product expertise with AI and SaaS offerings and has vast international experience in the U.S., Australia, India, Singapore, UK, France, Germany, New Zealand, Italy and Spain. Ms Bianchi's value to the 4DMedical Board of Directors lies in her CEO, board, and senior executive track record in financial services, global listed billion dollar tech corporations, tech start ups, tier 1 management consultancies, public sector organisations, and international research operations. Her governance, strategy and capital raising experience has helped her lead corporations in periods of growth, guiding them in the pivot to stock market listings and international sales. Ms Bianchi is an independent director and is Chair of the Audit and Risk Committee.
|Mr Julian Bernard Kingsley Sutton||Non-Executive Director||Sep 2017||
Mr Sutton started his career in 1995 as an actuarial analyst for Towers Perrin in Melbourne where he consulted to some of Australia's largest superannuation funds. He later transferred with Towers Perrin to Brussels and then London, where he worked predominantly in an asset consulting capacity. In 2002, Mr Sutton joined Credit Suisse Asset Management in London as an assistant portfolio manager in their Multi Manager team. Driven by strong performance, the team grew assets under management ten fold from GBP50 million to GBP500 million over the following two years. In 2004, Mr Sutton joined Schroders Investment Management as a Senior Portfolio Manager in the Multi Asset team, responsible for the management of a suite of investment funds with assets under management in excess of USD1 billion. These funds were invested on a global basis and had exposure to a broad range of asset classes including private equity, hedge funds, property, commodities, equities, bonds and cash. After seven years with Schroders, Mr Sutton returned to Australia with entrepreneurial ambitions. Mr Sutton established a sales and marketing business that helps best in class international fund management companies establish a presence in the Australian and New Zealand market. Currently, Mr Sutton is responsible for the sales and marketing function of Brown Advisory in Australia. Mr Sutton is a member of the Remuneration and Nomination Committee.
|Ms Melanie Jaye Leydin||Company Secretary||Feb 2022||
|Melanie Jaye Leydin||Company Secretary||
|National Nominees Limited||16,355,854||7.88%|
|JP Morgan Nominees Australia Pty Limited||9,127,791||4.40%|
|Ryder Innovation Fund LP||6,290,475||3.03%|
|BNP Paribas Nominees Pty Ltd Hub24 Custodial Serv Ltd||6,149,690||2.96%|
|HSBC Custody Nominees (Australia) Limited||4,821,206||2.32%|
|BNP Paribas Noms Pty Ltd||4,542,208||2.19%|
|HSBC Custody Nominees (Australia) Limited A/C 2||2,695,298||1.30%|
|CS Third Nominees Pty Limited||2,399,067||1.16%|
|BNP Paribas Nominees Pty Ltd||1,814,406||0.87%|
|Citicorp Nominees Pty Limited||1,670,998||0.81%|
|Truebell Capital Pty Ltd||1,258,064||0.61%|
|FCR Daunt Pty Ltd||1,250,000||0.60%|
|AAX Pty Ltd||1,200,000||0.58%|
|Mr Dean Vincent Egan||1,180,905||0.57%|
|Alltogether Pty Ltd||1,115,000||0.54%|
|Wal Assets Pty Ltd||1,103,055||0.53%|
|Lefkios Michael & Helen Michael||1,004,819||0.48%|
|Harry Maglis & Chrisy Maglis||1,000,000||0.48%|
|Edward Jerome Burke & Mary Jane Sinobio||1,000,000||0.48%|